Abstract
Twenty-nine patients with biopsy-confirmed metastatic melanoma (17) or metastatic renal cell carcinoma (12) were treated with escalating doses of recombinant human interleukin-2 (IL-2) administered as weekly 24-h intravenous infusions. Patients received from 3 to 12 × 106 C.U./m2 (18-72 × 106 I.U./m2) weekly over a treatment period of 1 to 16 weeks, with a median of eight weekly cycles administered. Patients in all treatment groups experienced non-life-threatening systemic side effects consisting of fever, nausea, vomiting, fluid retention, and diarrhea. Grade III hypotension was seen in four of six patients (67%) at 12 × 106 C.U./m2, and represented the dose-limiting toxicity. Grade IV hypotension occurred in 1 of 14 patients at 6 × 106 C.U./m2; no other grade IV toxicities were observed. Grade III fever occurred in 3 of 11 patients (27%) treated at 3 × 106 C.U./m2, 3 of 14 patients (21%) at 6 × 106 C.U./m2, and 3 of 6 patients (50%) at 9 × 106 C.U./m2. An objective response was observed in 3 of 28 evaluable patients (10%): 1 complete response and 1 partial response in renal cell cancer, and 1 partial response in a melanoma patient. We conclude that for future studies, the recommended dose of IL-2 given as a weekly 24-h infusion is 9 × 106 C.U./m2 and that a low rate of objective tumor response can be obtained in patients with melanoma and renal cell carcinoma using this regimen:
Original language | English (US) |
---|---|
Pages (from-to) | 57-62 |
Number of pages | 6 |
Journal | Journal of Immunotherapy |
Volume | 10 |
Issue number | 1 |
DOIs | |
State | Published - Feb 1991 |
Keywords
- Interleukin-2
- Metastatic melanoma
- Metastatic renal cell carcinoma
- Phase I study
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Pharmacology
- Cancer Research